Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

05 AUG -4 PM 3: 44

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name		
Organization Jennings Policy Strategies, Inc.		
2. Address Check if different than previously reported		
Address1 1001 G Street, NW Suite 600 East		
City Washington State	DC Zip Code	20001 Country U
3. Principal place of business (if different than line 2)	••••••	
City State City State	Zip Code Zip or Country	Country
4a. Contact Name b. Telephone number Prefix Full Name	c. E-mail	5. Senate ID#
Mr. Christoph Jennings (202) 879-9344 ccj	@jenningsps.com	64656-
General Motors Corp.		6. House ID # 355470
9. Check if this filing amends a previously filed version of this report	ary 1-June30) 🗷 (OR Year End (July 1-December 11, No Lobbying Ac
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report □ ⇒ Termination Dat INCOME OR EXPENSES - Complete Either Line	12 OR Line 13	11. No Lobbying Ac
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date INCOME OR EXPENSES - Complete Either Line 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was:	12 OR Line 13 EXPENSES relating twere:	11. No Lobbying Ac
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report □ □ Termination Date INCOME OR EXPENSES - Complete Either Line 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 □	EXPENSES relating twere: Less than \$10,000	11. No Lobbying Ac 13. Organizations to lobbying activities for this reporti
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report □ □ Termination Date INCOME OR EXPENSES - Complete Either Line 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 □	12 OR Line 13 EXPENSES relating twere:	11. No Lobbying Ac
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date INCOME OR EXPENSES - Complete Either Line 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more \$\$\text{\$\text	EXPENSES relating twere: Less than \$10,000 \$10,000 or more 14. REPORTING MI	11. No Lobbying Ac 13. Organizations to lobbying activities for this reporti
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report □ □ Termination Date INCOME OR EXPENSES - Complete Either Line 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 □	EXPENSES relating twere: Less than \$10,000 \$10,000 or more 14. REPORTING MI accounting method. S Method A. R. Method B. R.	11. No Lobbying Ac 13. Organizations to lobbying activities for this reporti

Printed Name and Title

Filing #3efd312c-fa31-4a57-b372-f53f73973077 - Page 1 of 10

Unristopher Jennings & President

LD-2DS (Rev. 4/03)

Page _1

Registrant Name_	Jennings Policy Strate	gies, Inc.	Client Name General Motors Corp.
engaged in lobby		lient during the re	ecessary to reflect the general issue areas in which the eporting period. Using a separate page for each conneeded.
15. General issu	e area code HCR - He	alth Issues	(one per page)
16. Specific lobb	bying issues		Add page to continue specific issues description for this issue 🔊
Medicare final -Advocated f medications	ancial support of retiree or policies that encoura as well as the removal or support for independ	health plans prog age the developm of barriers to grea	are Modernization Act that includes workable viding pharmaceutical coverage ent of cost-effective generic alternatives to biological ater competition with the pharmaceuitcal marketplace aparing the clinical effectiveness of pharmaceutical
17. House(s) of	Congress and Federal	agencies contact	ed Check if None
HHS	presentatives	d og a tobbyggt in	thic icona over
First Name	Name Last Name	u as a 1000yist iii Suffix	Covered Official Position (if applicable)
Christopher	Jennings	Sullix	
Yvette	Shenouda		

19. Interest of ea	ach foreign entity in th	ie specific issues	listed on line 16 above Check if None

Printed Name and Title Christopher Jennings, President

LD-2DS (REV. 4/03)

Page 2

Registrant Name _	Jennings Policy Strate	gies, Inc.	Client Name General Motors Corp.
engaged in lobby		lient during the re	ecessary to reflect the general issue areas in which the eporting period. Using a separate page for each connected.
15. General issue	e area code PHA - Ph	armacy	(one per page)
16. Specific lobb	oying issues		Add page to continue specific issues description for this issue 🖇
Medicare final -Advocated for medications	ancial support of retiree or policies that encoura as well as the removal or support for independ	health plans prov ge the developme of barriers to grea	are Modernization Act that includes workable viding pharmaceutical coverage ent of cost-effective generic alternatives to biological atter competition with the pharmaceuitcal marketplace aparing the clinical effectiveness of pharmaceutical
17. House(s) of	Congress and Federal	agencies contacto	ed Check if None
Senate House of Rep HHS	presentatives		
18. Name of eac	ch individual who acte	d as a lobbyist in	this issue area Add a page to continue additing lobbyists for
First Name Christopher	Name Last Name Jennings	Suffix	Covered Official Position (if applicable)
Yvette	Shenouda		

,,,,.,.,		***************************************	

19. Interest of ea	ach foreign entity in th	e specific issues	listed on line 16 above Check if None

Printed Name and Title Christopher Tannings, President

LD-2DS (REV. 4/03)

Page 3

Registrant Name	Jennings Policy Strate	gies, Inc.	Client Name General Motors Corp.
engaged in lobb		ient during the re	ecessary to reflect the general issue areas in which the eporting period. Using a separate page for each connected.
15. General issu	e area code MMM - M	edicare/Medicaid	(one per page)
16. Specific lobb	bying issues		Add page to continue specific issues description for this issue
Medicare final -Advocated f medications	ancial support of retiree for policies that encoura as well as the removal for support for independ	health plans pro ge the developm of barriers to grea	are Modernization Act that includes workable viding pharmaceutical coverage ent of cost-effective generic alternatives to biological ater competition with the pharmaceuitcal marketplace aparing the clinical effectiveness of pharmaceutical
17. House(s) of	Congress and Federal	agencies contact	ed Check if None
HHS	presentatives ch individual who acte	d as a lobbyist in	this issue area Add a page to continue additing lobbyists for
First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Christopher	Jennings		
Yvette	Shenouda		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
***************************************		***************************************	

,			
10 Interest of a	ach foreign antity in th	a chanifia iccuae	listed on line 16 above Check if None
17. morest of c	ach roloigh chary iii ii	re abcertite taanea	TIONGE OIL 11110 TO BOOTO CHOCK II POIRC

Printed Name and Title Christopher Jennings, President
LD-2DS (REV. 4/03)

Registrant Name	Jennings Policy Strate	gies, Inc.	Client Name General Motors Corp.
engaged in lobb		lient during the re	ecessary to reflect the general issue areas in which the eporting period. Using a separate page for each conneeded.
15. General issu	e area code INS - Insu	rance	(one per page)
16. Specific lob	bying issues		Add page to continue specific issues description for this issue
Medicare fin- -Advocated to medications	ancial support of retiree for policies that encoura as well as the removal for support for independ	health plans prog ge the developm of barriers to grea	are Modernization Act that includes workable viding pharmaceutical coverage ent of cost-effective generic alternatives to biological ater competition with the pharmaceuitcal marketplace nparing the clinical effectiveness of pharmaceutical
17. House(s) of	Congress and Federal	agencies contact	ed Check if None
ннѕ	presentatives ch individual who acte	d as a lobbyist in	this issue area Add a page to continue additing lobbyists for
First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Christopher	Jennings		
Yvette	Shenouda		
· · · · · · · · · · · · · · · · · · ·			
,,,,,			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
······			
19. Interest of e	ach foreign entity in th	e specific issues	listed on line 16 above Check if None

Filing #3efd312c-fa31-4a57-b372-f53f73973077 - Page 9 of 10

Printed Name and Title Mutof LD-2DS (REV. 4/03)

Christopher Jennings, President

Page _5